Once-daily azithromycin in the treatment of adult skin and skin-structure infections

Journal of Antimicrobial Chemotherapy

Volumn 31, Issue , 1993, Pages 129-135

  Rodriguez Noriega E ^a   Amaya Tapia, G ^b   Aguirre Avalos, G ^b   Andrade Villanueva, J ^b   Peredo Gonzalez G ^b   Morfin Otero, R ^b   Esparza Ahumada, S ^b  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DICLOXACILLIN; MACROLIDE; PENICILLIN DERIVATIVE;

ADULT; ARTICLE; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PERSISTENT INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; SUPERINFECTION;

ABSCESS; ACUTE DISEASE; ADOLESCENT; ADULT; AZITHROMYCIN; COMPARATIVE STUDY; DICLOXACILLIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROMYCIN; FEMALE; HUMAN; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 0027250323     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/31.suppl_E.129     Document Type: Article

References (21)

1. Aronoff, S. C, Laurent, C. & Jacobs, M. R. (1987). In-vitro activity of erythromycin, roxithromycin and CP-62, 993 against common paediatric pathogens. Journal of Antimicrobial Chemotherapy 19, 275-6.
2. Barry, A. L., Jones, R. N. & Thomsbcrry, C. (1988). In-vitro activities of azithromycin (CP-62, 993), clarithromycin (A-56268; TE-031), crythromycin, roxithromycin, and clindamycin. Antimicrobial Agents and Chemotherapy 32, 752-4.
3. Bisno, A. L. (1984). Cutaneous infections: microbiologic and epidemiologic considerations. American Journal of Medicine 76, Suppl. 5A. 172-9.
4. Dunkin, K. T., Jones, S. & Howard, A. J. (1988). The in-vitro activity of CP-62, 993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci. Journal of Antimicrobial Chemotherapy 21, 405-11.
5. Fleisher, G., Ludwig, S. & Campos, J. (1980). Ccllulitis: bacterial etiology, clinical features, and laboratory findings. Journal of Pediatrics 97, 591-3.
6. Foulds, G., Shepard, R. M. & Johnson, R. B. (1990). The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 73-82.
7. Girard, A. E., Girard, D., English, A. R., Gootz, T. D., Cimochowski, C. R., Faiella, J. A. et al. (1987). Pharmacokinetic and in-vivo studies with azithromycin (CP-62, 993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 31, 1948-54.
8. Girard, A. E., Girard, D. & Retsema, J. A. (1990). Correlation of the extravascular pharmacokjnetics of azithromycin with in-vivo efficacy in models of localized infection. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 61-71.
9. Gladue, R. P., Bright, G. M., Isaacson, R. E. & Newborg, M. F. (1989). In-vitro and in-vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 33, 277-82.
10. Gladue, R. P. & Snider, M. E. (1990). Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrobial Agents and Chemotherapy 34, 1056-60.
11. Hardy, D. J., Hensey, D. M., Beyer, J. M., Vojtko, C, McDonald, E. J. & Fernandes, P. B. (1988). Comparative in-vitro activities of new 14-, 15-and 16-mcmbercd macrolides. Antimicrobial Agents and Chemotherapy 32, 1710-9.
12. Kirst, H. A. & Sides, G. D. (1989). New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrobial Agents and Chemotherapy 33, 1419-22.
13. Mallory, S. B. (1991). Azithromycin compared with cephalexin in the treatment of skin and skin structure infections. American Journal of Medicine, 91, Suppl. 3A, 36S-9S.
14. Neu, H. C. (1991). Clinical microbiology of azithromycin. American Journal of Medicine 91, Suppl. 3A, 12S-8S.
15. Perez-Ruvalcaba, J. A., Quintero-Perez, N. P., Morales-Reyes, J. J., Huitron-Ramircz, J. A., Rodriguez-Chagollan, J. J. & Rodriguez-Noriega, E. (1987). Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections. American Journal of Medicine 82, Suppl. 4A. 242-6.
16. Retsema, J. A., Girard, A. E., Girard, D. & Milisen, W. B. (1990). Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in-vivo. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 83-9.
17. Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G. et al. (1987). Spectrum and mode of action of azithromycin (CP-62, 993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrobial Agents and Chemotherapy 31, 1939-47.
18. Santos, J. I., Jacobson, J. A., Swensen, P. & Palmer, W. M. (1981). Cellulitis: treatment with cefoxitin compared with multiple antibiotic therapy. Pediatrics 67, 887-90S
19. Sapico, F. L., Witte, J. L., Canawati, H. N., Montgomerie, J. Z. & Bessman, A. N. (1984). The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Reviews of Infectious Diseases 6, Suppl. 1, S171-6.
20. Schentag, J. J. & Ballow, C. H. (1991). Tissue-directed pharmacokinetics. American Journal of Medicine 91, Suppl. 3A, 5S-11S.
21. Shepard, R. M. & Falkner, F. C. (1990). Pharmacokinetics of azithromycin in rats and dogs. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 49-60.